Nagoya City University , abbreviated to Meishidai , is a public university in Japan. The main campus is located in Mizuho-ku, Nagoya City. Other three campuses are also located in the city. As of 2011, the university was the highest ranked public university that is not a national university in Japan. Wikipedia.
Method For Measuring Glycoprotein, Method For Examining Liver Desease, Reagent For Quantitative Determination Of Glycoprotein And Glycan-Marker Glycoprotein As An Index For Clinical Conditions Of Liver Disease
Sysmex Corporation, National Center For Global Health And Medicine, Nagoya City University, Japan National Institute of Advanced Industrial Science and Technology | Date: 2013-10-11
An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease. The method for measuring a glycoprotein is characterized in that: the glycoprotein is at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject; when the glycoprotein is AGP, AGP binding to a first lectin selected from AOL and MAL is measured; and when the glycoprotein is M2BP, M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII is measured.
Nagoya City University | Date: 2011-06-23
It becomes possible to stably deliver an inhaled particulate medicine to a targeted part for administration while reducing burdens on a patient. When supplying the particulate medicine into a body by an airflow, a multi-layer flow composed of a core airflow (A) and a clad airflow (B) outside the core airflow is used as the airflow. The medicine is dispersed in the core airflow (A) and velocity of the clad airflow (B) is set higher than that of the core airflow (A). The medicine dispersed in the core airflow (A) reaches the targeted part for administration while the medicine is protected by the clad airflow (B) without contacting a larynx and the like. A cross-sectional area of the airflow is set smaller than that of the larynx. The airflow is supplied to an upper side of the larynx.
Nagoya City University and Nagasaki University | Date: 2011-02-09
The present invention identifies a compound which binds to the PAH1 domain of mSin3B that specifically binds to neural restrictive silencer factor NRSF, and uses the compound as a prophylactic and/or a therapeutic for diseases associated with abnormal expression of neural restrictive silencer factor NRSF/REST or abnormal expression of genes targeted by NRSF/REST, such as Huntingtons disease, medulloblastoma and neuropathic pain. The present invention provides a pharmaceutical composition comprising a substance capable of binding to the PAH1 domain of mSin3B, e.g., a compound represented by the following formula (I), a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof: wherein n represents 0 or 1; R
Sanwa Kagaku Kenkyusho Co. and Nagoya City University | Date: 2012-02-01
A pharmaceutical for preventing or treating a disorder accompanied by ocular angiogenesis and/or increased ocular vascular permeability, composed of a combination of an anti-VEGF agent, and a pyrrolo[1,2-a]pyrazine derivative represented by a general formula (I): in the formula, R
Nucleic Acid Construct Comprising Nucleic Acid Derived From Genome Of Hepatitis C Virus Of Genotype 1B, Hepatitis C Virus Genome-Replicating Cells Transfected With The Same, And Method For Producing Infectious Hepatitis C Virus Particles
Japan Atomic Energy Agency, Nagoya City University and Toray Industries Inc | Date: 2012-03-30
A subgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and a fullgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and infectious HCV particle-producing ability, each derived from a novel HCV of genotype 1b, are provided. Particularly, a subgenomic replicon RNA (nucleic acid) and a fullgenomic replicon RNA (nucleic acid), each derived from an HCV genome of the NC1 strain which is a novel HCV genotype 1b isolated from a patient with acute severe hepatitis C, are provided.